Press Release on the occasion of the visit of the President of the Republic of Mozambique to Fábrica Nacional de Medicamentos – FNM on 16/09/2024

Login

Register

http://www.clubofmozambique.com/

Press Release on the occasion of the visit of the President of the Republic of Mozambique to Fábrica Nacional de Medicamentos – FNM on 16/09/2024

2:06 CAT | 19 Sep 2024

Photo courtesy: Fabrica Nacional de Medicamentos

Fabrica Nacional de Medicamentos SA (FNM) proudly announces that it has been granted World Health Organization Prequalification for international manufacture of medicines which implies, medicines manufactured in FNM is of the highest quality and of International standards, marketable in International markets.

This prestigious WHO PQ certification is not just a recognition of the factory’s compliance with the highest international manufacturing standards, but also a testament to Mozambique’s growing capacity to manufacture world-class pharmaceuticals. It enables FNM to supply its products not only to Mozambique’s National Health Service but also to other nations and organizations including developed Countries.

Since its inception in 2015, FNM has been dedicated to serving Mozambique’s health security needs, producing over 1 bn doses a year and about 85 essential medicines, including antihypertensive, antibiotics, anticonvulsants, antihistamines, antidiabetics, antifungals, analgesic, antibacterial, antacids, antidiarrheal, vitamins, antimalarial and antivirals. By ensuring the constant availability of these medicines in the Country, the company has played a vital role in stabilizing the supply chain for essential drugs. This has been made possible through close collaboration with Mozambique’s Ministry of Health and the National Regulatory Authority, ANARME. Both institutions have been instrumental in fostering a regulatory environment that encourages innovation and growth in local pharmaceutical manufacturing that has made this achievement possible. With their support, FNM are partnering international manufacture of repute like Mylan and Viatris to address Mozambique’s requirement across wide range of therapeutic areas to transfer the latest technologies for domestic manufacturing.

With the WHO PQ certification in hand, FNM is expanding its production capabilities as a major producer in Africa already one of the three best manufacturers in Sub-Saharan Africa. The company is investing in its manufacturing capabilities, with advanced technologies to increase production efficiency and capacity building. FNM and Mozambique Holdings, Lda has partnered with MISAU Government of Mozambique to rehabilitate government owned Sociedade Medicamentos de Moçambique – SMM, their oral solid dosage facility in Machava and building a state-of-the-art liquid pharmaceutical factory at the same site, for injectables and Vaccines

Fmfpr-fmf

Founded in 2015, FNM is the largest Mozambican pharmaceutical manufacturer promoted by Mozambique Holdings Group of companies, specializing in the production of essential generic drugs through 6 production lines in 2 manufacturing blocks. The company has partnered with Mozambique’s National Health Service and CMAM to provide critical medications to the Mozambique market, focusing on ensuring the availability of high-quality, affordable medicines. FNM is committed to playing a pivotal role in the future of healthcare in Mozambique and across the region. For this purpose, FNM has partnered with Government of Mozambique and IGEPE to rehabilitate and revitalize the government owned SMM, setting up a state-of-the-art laboratory and testing facilities and compliance standards to match international stipulations so that all production facilities can eventually be prequalified for international production by WHO.

Fmfpr.fmf_